A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Udai Banerji; Natalie Cook; Alan Anthoney; Ruth Plummer; William D. Tap; Jeffry T. Evans; Lee D. Cranmer; Christopher Plummer; Paul Loadman; Gezim Lahu; Huw S. Jones; Nelson Kinnersley; Fiona McLaughlin; Chris Twelves

doi:10.1158/1538-7445.AM2024-CT188

A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Udai Banerji, Natalie Cook, Alan Anthoney, Ruth Plummer, William D. Tap, Jeffry T. Evans, Lee D. Cranmer, Christopher Plummer, Paul Loadman, Gezim Lahu, Huw S. Jones, Nelson Kinnersley, Fiona McLaughlin, Chris Twelves

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	CT188
Number of pages	2
Journal	Cancer Research
Volume	84
Issue number	7 Supplement
DOIs	https://doi.org/10.1158/1538-7445.AM2024-CT188
Publication status	Published - 1 Apr 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1538-7445.AM2024-CT188

Cite this

Banerji, U., Cook, N., Anthoney, A., Plummer, R., Tap, W. D., Evans, J. T., Cranmer, L. D., Plummer, C., Loadman, P., Lahu, G., Jones, H. S., Kinnersley, N., McLaughlin, F., & Twelves, C. (2024). A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. Cancer Research, 84(7 Supplement), Article CT188. https://doi.org/10.1158/1538-7445.AM2024-CT188

@article{23f9df4a3f3f42ba956573f1f5555ba6,

title = "A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors",

author = "Udai Banerji and Natalie Cook and Alan Anthoney and Ruth Plummer and Tap, {William D.} and Evans, {Jeffry T.} and Cranmer, {Lee D.} and Christopher Plummer and Paul Loadman and Gezim Lahu and Jones, {Huw S.} and Nelson Kinnersley and Fiona McLaughlin and Chris Twelves",

year = "2024",

month = apr,

day = "1",

doi = "10.1158/1538-7445.AM2024-CT188",

language = "English",

volume = "84",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "7 Supplement",

}

Banerji, U, Cook, N, Anthoney, A, Plummer, R, Tap, WD, Evans, JT, Cranmer, LD, Plummer, C, Loadman, P, Lahu, G, Jones, HS, Kinnersley, N, McLaughlin, F & Twelves, C 2024, 'A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors', Cancer Research, vol. 84, no. 7 Supplement, CT188. https://doi.org/10.1158/1538-7445.AM2024-CT188

A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. / Banerji, Udai; Cook, Natalie; Anthoney, Alan et al.
In: Cancer Research, Vol. 84, No. 7 Supplement, CT188, 01.04.2024.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

AU - Banerji, Udai

AU - Cook, Natalie

AU - Anthoney, Alan

AU - Plummer, Ruth

AU - Tap, William D.

AU - Evans, Jeffry T.

AU - Cranmer, Lee D.

AU - Plummer, Christopher

AU - Loadman, Paul

AU - Lahu, Gezim

AU - Jones, Huw S.

AU - Kinnersley, Nelson

AU - McLaughlin, Fiona

AU - Twelves, Chris

PY - 2024/4/1

Y1 - 2024/4/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001203184200151&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1158/1538-7445.AM2024-CT188

DO - 10.1158/1538-7445.AM2024-CT188

M3 - Meeting Abstract

SN - 0008-5472

VL - 84

JO - Cancer Research

JF - Cancer Research

IS - 7 Supplement

M1 - CT188

ER -

A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

UN SDGs

Access to Document

Other files and links

Cite this